Biocon Biologics and Civica collaborate to expand insulin Aspart access in US

Bengaluru-based Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, and Civica, Inc., a not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, have announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States (US).

- 

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug sub